Prior authorization — none specified

No prior authorization statements are specified in this policy for routine serum lipase testing for suspected acute pancreatitis. Providers should follow applicable member-specific prior authorization rules per the plan and submit supporting documentation when required by the member’s benefit.

Prior authorization may apply to repeat/serial testing

Prior authorization may be required or considered for repeated or serial amylase/lipase testing or testing patterns that reflect overuse; routine repeat testing after diagnosis has limited value and may trigger utilization management review.

• Policy notes repeat inpatient/ambulatory overuse and potential utilization management actions.
• CADTH and evidence cited do not recommend routine repeat lipase testing and support minimum retesting intervals.

Code reference provided; no PA tied to codes in policy

The policy lists CPT/PL procedure codes for reference (e.g., 82150, 83690, 86140, 86141) but does not impose an explicit prior authorization requirement tied to these codes within the policy text.

• Codes referenced include: 82150 (amylase); 83690 (lipase); 86140 (CRP); 86141 (hsCRP).

Policy coding updated — CPT 86141 added; follow PA rules as applicable

The policy’s coding list was updated to add CPT code 86141 (hsCRP); providers should follow plan-specific prior authorization processes where applicable when billing these or other listed codes.

• 86141 was added in the revision history.
• Follow member plan prior authorization rules as applicable.

Step therapy — not specified

No step therapy requirements are described in this policy for pancreatic enzyme testing.

Preferred testing sequence — single enzyme testing (lipase preferred)

Prefer ordering a single enzyme test rather than both; serum lipase is the preferred initial diagnostic test and concurrent amylase+lipase testing is discouraged because it increases cost with marginal additional diagnostic benefit.

• Guidelines (ACG, ASCP/Choosing Wisely) recommend preferring lipase over amylase.
• Testing both amylase and lipase is discouraged due to limited added diagnostic yield.

Preferred initial test — serum lipase preferred

Order serum lipase as the preferred initial diagnostic test for suspected acute pancreatitis; avoid ordering both amylase and lipase simultaneously as lipase is more sensitive and remains elevated longer.

• ACG and ASCP/Choosing Wisely recommend lipase over amylase for initial diagnosis.
• NASPGHAN and other guideline references support lipase as preferred.

(No action specified)

(Placeholder inventory item — no additional action specified in the policy text.)

Clinical indication required — document signs/symptoms of acute pancreatitis

When ordering serum lipase, document signs and symptoms consistent with acute pancreatitis (for example: epigastric pain, nausea, vomiting, abdominal tenderness, fever, hypotension, Cullen or Grey Turner signs) to support medical necessity.

• Note 1 lists required clinical features to support testing (epigastric pain, nausea, vomiting, abdominal tenderness, fever, hypotension, Cullen/Grey Turner signs, etc.).

Diagnostic documentation — document ≥2 diagnostic criteria

Support the diagnosis in the medical record by documenting at least two of the diagnostic criteria: characteristic abdominal pain, amylase or lipase ≥3× upper limit of normal, or imaging consistent with pancreatitis.

• NASPGHAN/Atlanta/AGA/ACG define diagnosis as ≥2 of these criteria.
• Document enzyme values with reference to the laboratory URL when applicable (≥3× ULN).

Documentation to support testing — record signs and enzyme values (≥3× ULN)

Document the clinical signs (abdominal pain suggestive of acute pancreatitis) and specify enzyme lab values when amylase or lipase meet or exceed three times the upper limit of normal (≥3× URL); preferentially document lipase results when available.

• Record numeric enzyme values and laboratory reference ranges to demonstrate ≥3× ULN when used for diagnosis.
• Prefer including lipase result in documentation due to greater diagnostic utility.

Documentation and coding standards — follow coding rules and support medical necessity

Follow CPT/HCPCS/ICD-10/NCCI coding and Healthfirst claim-edit rules when submitting claims; ensure documentation in the medical record supports the medical necessity of ordered tests to avoid claim denials or recoupment.

• Healthfirst claim edits follow national coding standards (NCCI, NCD/LCD, CPT/HCPCS/ICD-10) and failure to follow guidelines may result in denial/recoupment.

Tests not covered for AP evaluation — do not order/bill for listed tests for AP

For diagnosis, assessment, prognosis, or severity determination of acute pancreatitis, the following tests do not meet coverage criteria and should not be billed for those indications: serum or urine trypsin/trypsinogen/TAP, CRP, IL-6, IL-8, procalcitonin, and measurement of amylase except when ordered for pancreatic cyst fluid analysis.

• Policy explicitly lists these tests as not meeting coverage criteria for AP evaluation.
• Amylase is not covered except for pancreatic cyst fluid analysis.

Outpatient frequency limit — ≤1 serum lipase test per outpatient day

Outpatient serum lipase testing ordered more than once per outpatient day may exceed the policy’s stated outpatient limit (no more than one test per outpatient day) and is at risk of denial unless clinically justified and documented.

• Revision history and coverage criteria state outpatient measurement is limited to no more than one test per day.
• CADTH and policy text recommend minimum retesting intervals and advise against routine repeat outpatient testing.

Unnecessary repeat testing — avoid routine serial enzyme testing

Avoid repeat or serial amylase/lipase testing when not clinically indicated; routine daily or serial testing after diagnosis contributes to overutilization and may be subject to utilization management denial.

• Evidence cited shows frequent unnecessary repeat testing (mean unnecessary additional serial tests of 2.4–2.8).
• Guidelines indicate daily measurement after diagnosis has limited value.

Risk of denial for repeat lipase monitoring — monitoring not routinely supported

Reordering lipase tests solely for monitoring established acute or chronic pancreatitis is discouraged and may be considered inappropriate except when there is clinical suspicion of acute-on-chronic pancreatitis or new/worsening signs; such repeat monitoring may be denied if not justified.

• CADTH guidance: do not reorder lipase for monitoring established acute or chronic pancreatitis; exception for suspected acute-on-chronic disease.

Denial risk for improper coding — ensure correct coding and documentation

Claims may be denied or recouped for failure to follow proper coding, billing, and reimbursement policy guidelines, including national coding edits, modifier usage, duplicates, and other claim edits; ensure accurate code selection and supporting documentation.

• Policy warns that failure to follow coding/billing rules could result in denial and recoupment.
• Providers should ensure documentation matches billed services.